VIRX: viracta.com Company Value to Net Income

Viracta Therapeutics, Inc. - graphic logo of issuer VIRX

The Viracta Therapeutics (VIRX) price chart demonstrates the -0.10 metric, which correlates with the biotech firm's activities in developing therapies for Epstein-Barr virus-driven lymphomas. The business relies on expansion within the targeted drug segment, aiming to capture a significant share of the oncology market. Professional management is focused on bringing unique medications to market through the precise administration of clinical trial stages.

Price to Earnings Ratio: Viracta (VIRX) for 07/04/2022 - 02/08/2025

Comprehensive metric breakdowns and analytics for Viracta Therapeutics Inc. (VIRX)

General company analysis:Viracta Therapeutics, Inc.
Flagship merchandise of Viracta Therapeutics, Inc.

Viracta Therapeutics (VIRX) competes in the targeted lymphoma drug development segment. The P/E ratio measures the market value of a single unit of profit, determining the investment payback period through discounted cash flows. Investors weigh current research expenditures against potential revenue. Expectations for clinical trial results directly impact the company's P/E ratio. The dynamics of this metric reflect the market's valuation of the issuer's future success.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|OKUR - Price to Earnings Ratio|GDTC - P/E Multiple|Curis, Inc. (CRIS) - Price to Earnings Ratio|Price to Earnings Ratio Apollomics, Inc.|Price to Earnings Ratio THAR|Price to Earnings Multiple ADVB (Advanced Biomed)|Price to Earnings Ratio GNPX (Genprex, Inc)|CLDI: Market Cap to Net Income|Price to Earnings Ratio sunshinebiopharma.com SBFM|XBIO - Price to Earnings Ratio|SLRX: Price to Earnings Ratio|Purple Biotech - Market Price to Net Income Ratio|American Oncology Network (AONC) - Price to Earnings Ratio|Price to Earnings Multiple BGNE|Price to Earnings Ratio CKPT|Price to Earnings Ratio ELEV|P/E Multiple ICAD|P/E Multiple Ikena Oncology Inc. (IKNA)|P/E Multiple NTBL (Notable Labs Ltd)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV